This site complies with the HONcode standard for trustworthy health information:
verify here.

Rewarding for
you and us
Defeat Diabetes Foundation

Defeat Diabetes
Foundation
150 153rd Ave,
Suite 300
Madeira Beach, FL 33708

Transdermal GLP-1 Patch for Type 2 Diabetes

Posted: Wednesday, September 29, 2010

TransPharma Medical, Ltd., announced the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of Type 2 diabetes.

The Phase 1 study was a three-way crossover study designed to evaluate the pharmacokinetic (PK) profile and assess safety and tolerability of two doses of ViaDerm-GLP1 agonist in healthy volunteers, as compared to a subcutaneous injection of Exenatide (Byetta). Each volunteer received all three treatments with a washout period of one week between treatments.

The results of the study demonstrate ViaDerm-GLP1 agonist to be safe and well-tolerated with a preferable extended PK profile compared to an injection of Exenatide (Byetta). Transdermal application of ViaDerm-GLP1 agonist resulted in therapeutic GLP1 blood levels for approximately 13 hours compared to 6 hours of the injected form. In addition, ViaDerm-GLP1 agonist was demonstrated to be biologically active based on changes in glucose levels during the treatment. TransPharma has initiated enrollment of Type 2 diabetic patients to a phase 1b clinical trial using its dry form, extended release state-of-the-art patch formulation of GLP1 agonist.

The drug displays biological properties similar to human glucagon like peptide 1 (GLP1), a regulator of glucose metabolism and insulin secretion. Currently, the drug is administered twice daily to Type 2 diabetes patients via injections.

Dr. Daphna Heffetz, CEO of TransPharma Medical, said, "We are very pleased with the results of this study, which demonstrate significant advantages of our ViaDerm-GLP1 agonist over the injectable marketed product. We have clearly demonstrated a preferable extended drug PK profile when the molecule is administered utilizing our ViaDerm system. The extended profile may allow for once daily painless transdermal administration in comparison to the current two daily injections treatment. We are looking forward to the results of the Phase 1b testing."

TransPharma's ViaDerm drug delivery system incorporates a handheld electronic device, which creates microscopic passageways through the outer layer of the skin allowing for transdermal delivery of a wide variety of drugs from a patch. The system provides a cost-effective, easy-to-use, self-administered solution that enables the safe, reproducible and accurate delivery of a broad range of product candidates, including hydrophilic small molecules peptides and proteins.

Source: http://www.diabetesincontrol.com/index.php?option=com_content&view=article&id=9844&catid=53&Itemid=8, TransPharma Medical, news release